Log in

NASDAQ:CALA - Calithera Biosciences Stock Price, Forecast & News

$4.81
+0.34 (+7.61 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$4.45
Now: $4.81
$5.29
50-Day Range
$3.21
MA: $5.88
$7.80
52-Week Range
$2.45
Now: $4.81
$8.04
Volume945,074 shs
Average Volume685,699 shs
Market Capitalization$311.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Read More
Calithera Biosciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CALA
CUSIPN/A
Phone650-870-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.25 million
Book Value$2.24 per share

Profitability

Net Income$-89,860,000.00

Miscellaneous

Employees79
Market Cap$311.11 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.


Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

How has Calithera Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CALA shares have decreased by 8.0% and is now trading at $4.81. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Calithera Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Calithera Biosciences.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Calithera Biosciences.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) released its earnings results on Wednesday, March, 11th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.02. View Calithera Biosciences' earnings history.

What price target have analysts set for CALA?

5 Wall Street analysts have issued 1-year target prices for Calithera Biosciences' shares. Their forecasts range from $6.00 to $7.00. On average, they anticipate Calithera Biosciences' share price to reach $6.67 in the next twelve months. This suggests a possible upside of 38.6% from the stock's current price. View analysts' price targets for Calithera Biosciences.

Has Calithera Biosciences been receiving favorable news coverage?

Media coverage about CALA stock has been trending somewhat positive this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Calithera Biosciences earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View the latest news aboutCalithera Biosciences.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,627,200 shares, an increase of 5.7% from the February 27th total of 1,540,000 shares. Based on an average daily trading volume, of 433,500 shares, the short-interest ratio is presently 3.8 days. Currently, 4.7% of the shares of the stock are short sold. View Calithera Biosciences' Current Options Chain.

Who are some of Calithera Biosciences' key competitors?

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and United Continental (UAL).

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:
  • Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 65)
  • Ms. Sumita Ray, Sr. VP, Gen. Counsel & Chief Compliance Officer (Age 45)
  • Dr. Keith Orford, Chief Medical Officer (Age 47)
  • Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 45)
  • Ms. Jennifer McNealey, VP of Investor Relations & Strategy

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (17.78%), Delphi Management Partners VIII L.L.C. (4.51%), Sofinnova Investments Inc. (2.71%), Renaissance Technologies LLC (2.24%), Point72 Asset Management L.P. (1.87%) and State Street Corp (1.58%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Susan Molineaux and Value Fund L P Biotechnology. View institutional ownership trends for Calithera Biosciences.

Which major investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Point72 Asset Management L.P., Oxford Asset Management LLP, Bank of America Corp DE, Prudential Financial Inc., Acadian Asset Management LLC, Jane Street Group LLC, and Cubist Systematic Strategies LLC. View insider buying and selling activity for Calithera Biosciences.

Which major investors are buying Calithera Biosciences stock?

CALA stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Delphi Management Partners VIII L.L.C., Sofinnova Investments Inc., Renaissance Technologies LLC, State Street Corp, Jacobs Levy Equity Management Inc., Geode Capital Management LLC, and AQR Capital Management LLC. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, Susan Molineaux, and Value Fund L P Biotechnology. View insider buying and selling activity for Calithera Biosciences.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $4.81.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $311.11 million and generates $22.25 million in revenue each year. The biotechnology company earns $-89,860,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Calithera Biosciences employs 79 workers across the globe. View additional information about Calithera Biosciences.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is http://www.calithera.com/.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]


MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  565
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe CALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel